296 related articles for article (PubMed ID: 22152690)
1. [Effect of the XRCC1 and XRCC3 genetic polymorphisms on the efficacy of platinum-based chemotherapy in patients with advanced non-small cell lung cancer].
Xu C; Wang X; Zhang Y; Li L
Zhongguo Fei Ai Za Zhi; 2011 Dec; 14(12):912-7. PubMed ID: 22152690
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
[TBL] [Abstract][Full Text] [Related]
3. Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers.
Yao CY; Huang XE; Li C; Shen HB; Shi MQ; Feng JF; Pan LX; Tang JH
Asian Pac J Cancer Prev; 2009; 10(5):859-64. PubMed ID: 20104979
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum.
Liao WY; Shih JY; Chang GC; Cheng YK; Yang JC; Chen YM; Yu CJ
J Thorac Oncol; 2012 Jun; 7(6):973-81. PubMed ID: 22551904
[TBL] [Abstract][Full Text] [Related]
5. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.
Jin ZY; Zhao XT; Zhang LN; Wang Y; Yue WT; Xu SF
Genet Mol Res; 2014 Mar; 13(3):7617-25. PubMed ID: 24737519
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of GSTP1, XRCC1 and XRCC3 polymorphisms in non-small cell lung cancer patients.
Ke HG; Li J; Shen Y; You QS; Yan Y; Dong HX; Liu JH; Shen ZY
Asian Pac J Cancer Prev; 2012; 13(9):4413-6. PubMed ID: 23167352
[TBL] [Abstract][Full Text] [Related]
7. Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients.
Chen X; Sun H; Ren S; Kim Curran V; Zhang L; Zhou S; Zhang J; Zhou C
Clin Transl Oncol; 2012 Mar; 14(3):207-13. PubMed ID: 22374424
[TBL] [Abstract][Full Text] [Related]
8. No association between XRCC1 polymorphisms and survival in non-small-cell lung cancer patients treated with platinum-based chemotherapy.
Yuan P; Liu L; Wu C; Zhong R; Yu D; Wu J; Xu Y; Nie S; Miao X; Sun Y; Xu B; Lin D
Cancer Biol Ther; 2010 Nov; 10(9):854-9. PubMed ID: 20814250
[TBL] [Abstract][Full Text] [Related]
9. XRCC3 Thr241Met is associated with response to platinum-based chemotherapy but not survival in advanced non-small cell lung cancer.
Qiu M; Xu L; Yang X; Ding X; Hu J; Jiang F; Xu L; Yin R
PLoS One; 2013; 8(10):e77005. PubMed ID: 24116196
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of XRCC1 gene polymorphisms on platinum-based chemotherapy in advanced non-small cell lung cancer patients: a systematic review and meta-analysis.
Wu J; Liu J; Zhou Y; Ying J; Zou H; Guo S; Wang L; Zhao N; Hu J; Lu D; Jin L; Li Q; Wang JC
Clin Cancer Res; 2012 Jul; 18(14):3972-81. PubMed ID: 22705987
[TBL] [Abstract][Full Text] [Related]
11. Association between the XRCC1 polymorphisms and clinical outcomes of advanced NSCLC treated with platinum-based chemotherapy: a meta-analysis based on the PRISMA statement.
Li DJ; Xiao D
BMC Cancer; 2017 Jul; 17(1):501. PubMed ID: 28743242
[TBL] [Abstract][Full Text] [Related]
12. [Single nucleotide polymorphisms in XRCC1 and clinical response to platin-based chemotherapy in advanced non-small cell lung cancer].
Wang ZH; Miao XP; Tan W; Zhang XR; Xu BH; Lin DX
Ai Zheng; 2004 Aug; 23(8):865-8. PubMed ID: 15301704
[TBL] [Abstract][Full Text] [Related]
13. [XRCC1 and XPD genetic polymorphisms predict clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].
Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Sun Y; Zhang XR; Xu BH; Lin DX
Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):196-9. PubMed ID: 16875604
[TBL] [Abstract][Full Text] [Related]
14. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
Liao WY; Ho CC; Tsai TH; Chen KY; Shih JY; Yu CJ
Lung Cancer; 2018 Apr; 118():90-96. PubMed ID: 29572009
[TBL] [Abstract][Full Text] [Related]
15. Association between XRCC1 and XRCC3 gene polymorphisms and risk of thyroid cancer.
Wang X; Zhang K; Liu X; Liu B; Wang Z
Int J Clin Exp Pathol; 2015; 8(3):3160-7. PubMed ID: 26045834
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphisms of GSTP1 and XRCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) patients.
Zhou F; Yu Z; Jiang T; Lv H; Yao R; Liang J
Swiss Med Wkly; 2011; 141():w13275. PubMed ID: 22009704
[TBL] [Abstract][Full Text] [Related]
17. XRCC3 Thr241Met polymorphism and clinical outcomes of NSCLC patients receiving platinum-based chemotherapy: a systematic review and meta-analysis.
Shen XY; Lu FZ; Wu Y; Zhao LT; Lin ZF
PLoS One; 2013; 8(8):e69553. PubMed ID: 23940523
[TBL] [Abstract][Full Text] [Related]
18. [Correlation of the sensitivity of NP chemotherapy in non-small lung cancer with DNA repair gene XRCC1 polymorphism].
Hong CY; Xu Q; Yue Z; Zhang Y; Yuan Y
Ai Zheng; 2009 Dec; 28(12):1291-7. PubMed ID: 19958624
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenomics of platinum-based chemotherapy response in NSCLC: a genotyping study and a pooled analysis.
Chen J; Wang Z; Zou T; Cui J; Yin J; Zheng W; Jiang W; Zhou H; Liu Z
Oncotarget; 2016 Aug; 7(34):55741-55756. PubMed ID: 27248474
[TBL] [Abstract][Full Text] [Related]
20. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
Zhou C; Ren S; Zhou S; Zhang L; Su C; Zhang Z; Deng Q; Zhang J
Jpn J Clin Oncol; 2010 Oct; 40(10):954-60. PubMed ID: 20462983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
